Impact of Prior Radiation Treatment on Sipuleucel-T Product Parameters in PROCEED Patients von Furay, A, Nordquist, L.T, Dakhil, S.R, Green, N.B, Heath, E.I, Tutrone, R.F, Vogelzang, N.J, Armstrong, A.J, Cooperberg, M.R, Tyler, R.C, Whitmore, J.B, Higano, C.S

Volltext

1387P Final analysis of the phase Ib/II study of sabizabulin in men with metastatic castration-resistant prostate cancer who progressed on an androgen receptor targeting agent von Markowski, M.C., Eisenberger, M., Pieczonka, C., Rodriguez, D., Barnette, K.G., Getzenberg, R.H., Steiner, M.S., Saltzstein, D.R., Antonarakis, E.S., Tutrone, R.F.

Volltext

1386P 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate in patients with prostate cancer (NCT04729114) von Avitia, J.W., Bailen, J.L., Shore, N.D., Tutrone, R.F., Nordquist, L.T., Walling, J., Peterson, L., Schotzinger, R., Moore, W.R.

Volltext

Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide von Rathkopf, D.E., Smith, M.R., Ryan, C.J., Berry, W.R., Shore, N.D., Liu, G., Higano, C.S., Alumkal, J.J., Hauke, R., Tutrone, R.F., Saleh, M., Chow Maneval, E., Thomas, S., Ricci, D.S., Yu, M.K., de Boer, C.J., Trinh, A., Kheoh, T., Bandekar, R., Scher, H.I., Antonarakis, E.S.

Volltext

Exosome-based testing enhances shared decision-making and improves patient risk stratification von Tutrone, R.F., Donovan, M., Torkler, P., Tadigotla, V., Alter, J., Noerholm, M., Skog, J., Mckiernan, J.

Volltext

1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): Initial results from SPLASH von Hansen, A.R., Probst, S., Tutrone, R.F., Osman, M.M., Delpassand, E.S., Nordquist, L.T., Viglianti, B.L., Michalski, J.M., Beauregard, J-M., Oz, O.K., Courtney, K., Jensen, J., Wu, W., Fleshner, N., Sartor, O., Chi, K.N., Tagawa, S.T.

Volltext

Testosterone recovery for relugolix vs. leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study von Tombal, B., Tutrone, R.F., Saad, F., George, D.J., Bailen, J.L., Cookson, M.S., Saltzstein, D.R., Brown, B., Lu, S., Shore, N.D.

Volltext

Oral relugolix for androgen deprivation therapy in advanced prostate cancer: Detailed safety analysis from the randomized phase 3 HERO study von Tombal, B., Mehlhaff, B., Shore, N.D., George, D.J., Cookson, M.S., Saltzstein, D.R., Tutrone, R.F., Bailen, J.L, Brown, B., Langenberg, A.G.M., Lu, S., Fallick, M., Hanson, S., Saad, F.

Volltext

626 NX-1207 for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) von Shore, N.D, Tutrone, R.F

Volltext